vandetanib

Vandetanib is an oral small molecule tyrosine kinase inhibitor used primarily for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It acts by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, including vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptor (EGFR), and the RET proto-oncogene. Vandetanib also inhibits other kinases such as BRK, TIE2, members of the EPH receptor family, and Src kinase family. Its mechanism leads to reduced tumor cell proliferation and angiogenesis. The drug was originally developed by AstraZeneca and later rights were sold to Sanofi.

Brand names

Caprelsa

Other names

vandetanibZD6474ZD-6474ZD 6474Caprelsa